University of California, Los Angeles biochemists have mapped the structure of a key protein–RNA complex that is required for the assembly of telomerase, an enzyme important in both cancer and aging. The researchers found that a region at the end of the p65 protein that includes a flexible tail is responsible for bending telomerase's RNA backbone in order to create a scaffold for the assembly of other protein building blocks.
A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.
In life, we sort soiled laundry from clean; ripe fruit from rotten. Two Johns Hopkins engineers say they have found an easy way to use gravity or simple forces to similarly sort microscopic particles and bits of biological matter—including circulating tumor cells.
As the field of nanomedicine matures, an emerging point of contention has been what shape nanoparticles should be to deliver their drug or DNA payloads most effectively. A pair of new papers by scientists at The Methodist Hospital Research Institute (TMHRI) and six other institutions suggests these microscopic workhorses ought to be disc-shaped, not spherical or rod-shaped, when targeting cancers at or near blood vessels.
At a recent weekend conference of more than 30,000 specialists, experts reported seeing a major escalation in the arms race against cancer. Several new advances, including “smart” drugs, immune system aids, and treatments based on genetic pathways, offer new hope for battling previously intractable diseases.
Using a technique known as "nucleic acid origami," chemical engineers have built tiny particles made out of DNA and RNA that can deliver snippets of RNA directly to tumors, turning off genes expressed in cancer cells.
A laboratory test used to detect disease and perform biological research could be made more than 3 million times more sensitive, according to researchers who combined standard biological tools with a breakthrough in nanotechnology. The increased performance could improve the early detection of diseases and disorder by allowing doctors to detect far lower concentrations of telltale markers than was previously practical.
Scientists had originally thought they could create a “magic bullet” to patrol for cancer cells in the body, but only 5% of injected nanoparticles reach the targeted tumor using current delivery techniques. A Johns Hopkins University scientist is now working on techniques to specify nanoparticle size and shape and improve the chances that the drug will find its target.
Doctors have long known that treating patients with multiple cancer drugs often produces better results than treatment with just a single drug. Now, a study from Massachusetts Institute of Technology shows that the order and timing of drug administration can have a dramatic effect.
In order to reactivate silenced genes, a cell needs to remove certain “off” markers called methyl groups from the DNA. Scientists have recently shown that this process involves an intermediate step and an enzyme that also plays a role in the development of blood cancer. The finding could lead to new ideas for cancer-fighting therapies.
As vacationers prepare to spend time outdoors this summer, many of them will pack plenty of sunscreen in hopes it will protect their bodies from overexposure, and possibly from skin cancer. But researchers at Missouri University of Science and Technology are discovering that sunscreen may not be so safe after all.
Researchers have taken advantage of cells' physical properties to develop a new instrument that slams cells against a wall of fluid and quickly analyzes the physical response, allowing for the identification of cancer and other cell states without expensive chemical tags.
Both radiation and many forms of chemotherapy try to kill tumors by causing oxidative stress in cancer cells. New research from the University of Southern California on a protein that protects cancer and other cells from these stresses could one day help doctors to break down cancer cells' defenses, making them more susceptible to treatment.
Using light-harvesting nanoparticles to convert laser energy into plasmonic nanobubbles, researchers at Rice University, the University of Texas MD Anderson Cancer Center, and Baylor College of Medicine are developing new methods to inject drugs and genetic payloads directly into cancer cells. In tests on drug-resistant cancer cells, the researchers found that delivering chemotherapy drugs with nanobubbles was up to 30 times more deadly to cancer cells than traditional drug treatment.
Drugs made of protein have shown promise in treating cancer, but they are difficult to deliver because the body usually breaks down proteins before they reach their destination. To get around that obstacle, a team of Massachusetts Institute of Technology researchers has developed a new type of nanoparticle that can synthesize proteins on demand.
Nanotechnology offers powerful new possibilities for targeted cancer therapies, but the design challenges are many. Northwestern University scientists now are the first to develop a simple but specialized nanoparticle that can deliver a drug directly to a cancer cell's nucleus—an important feature for effective treatment.
Targeted therapeutic nanoparticles that accumulate in tumors while bypassing healthy cells have shown promising results in an ongoing clinical trial, according to a new paper. The nanoparticles feature a homing molecule that allows them to specifically attach cancer cells, and are the first such target particles to enter human clinical studies.
For the first time, University of Florida researchers have developed plant-based technology that could reduce America's dependence on foreign oil and may also help treat cancer. Known as lignin nanotubes, these cylindrical containers are smaller than viruses and tiny enough to travel through the body, carrying cancer patients' medicine.
Researchers at Brown University and Hasbro Children's Hospital have traced the molecular interactions that allow the protein survivin to escape the nucleus of a breast cancer cell and prolong the cell's life. The study may help in the development of better therapies and prognostics.
IDBS announced that King's Health Partners has deployed the Oncology Research Information System (ORIS), a platform that consolidates translational medicine data from multiple sites into one system. ORIS will help uncover new avenues for research into cancer causes and personalized treatments to improve outcomes for patients in London and advance cancer research in the U.K.
Therapeutic proteins, which provide cutting-edge treatments of cancer, diabetes, and countless other diseases, are among today's most widely consumed biopharmaceuticals. By introducing bottom-up carbohydrate engineering into common bacterial cells, Cornell University researchers have discovered a way to make these drugs cheaper and safer.
An international team of scientists has announced a new advance in the ability to target and destroy certain cancer cells. A group led by the University of Leicester has shown that particular cancer cells are especially sensitive to a protein called p21, which usually forces normal and cancer cells to stop dividing, but was recently shown in some cases to kill cancer cells.
Researchers at Brown University have created an implant that appears to deter breast cancer cell regrowth. Made from a common federally approved polymer, the implant is the first to be modified at the nanoscale in a way that causes a reduction in the blood-vessel architecture that breast cancer tumors depend upon, while also attracting healthy breast cells.
Cancer is usually attributed to faulty genes, but growing evidence from the field of cancer epigenetics indicates a key role for the gene "silencing" proteins that stably turn genes off inside the cell nucleus. A new study from Rice University and Baylor College of Medicine promises to speed research in the field by rapidly identifying the genes that epigenetic proteins can target for silencing.
In a prize-winning finding, a team of researchers at Duke University has determined the structure of a key molecule that can carry chemotherapy and anti-viral drugs into cells, which could help to create more effective drugs with fewer effects to healthy tissue.